Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewIbotenic acid
Description: NMDA agonist; also non selective mGlu agonist
Chemical Name: α-Amino-(3-hydroxy-5-isoxazolyl)acetic acid
Purity: ≥98% (HPLC)
Biological Activity for Ibotenic acid
Ibotenic acid is a NMDA and metabotropic glutamate receptor agonist.
Technical Data for Ibotenic acid
| M. Wt | 158.11 |
| Formula | C5H6N2O4 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 2552-55-8 |
| PubChem ID | 1233 |
| InChI Key | IRJCBFDCFXCWGO-UHFFFAOYSA-N |
| Smiles | NC(C(O)=O)C1=CC(O)=NO1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Ibotenic acid
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 1.58 | 10 | |
| 1.1eq. NaOH | 15.81 | 100 |
Preparing Stock Solutions for Ibotenic acid
The following data is based on the product molecular weight 158.11. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 6.32 mL | 31.62 mL | 63.25 mL |
| 5 mM | 1.26 mL | 6.32 mL | 12.65 mL |
| 10 mM | 0.63 mL | 3.16 mL | 6.32 mL |
| 50 mM | 0.13 mL | 0.63 mL | 1.26 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Ibotenic acid
References for Ibotenic acid
References are publications that support the biological activity of the product.
Johnston et al (1968) Central actions of ibotenic acid and muscimol. Biochem.Pharmacol. 17 2488 PMID: 5752907
Nakanishi (1992) Molecular diversity of glutamate receptors and implications for brain functions. Science 258 597 PMID: 1329206
Pin and Duvoisin (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 1 PMID: 7623957
Watkins and Evans (1981) Excitatory amino acid transmitters. Annu.Rev.Pharmacol.Toxicol. 21 165 PMID: 6112965
If you know of a relevant reference for Ibotenic acid, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Ibotenic acid, Ibotenic acid supplier, Non-Selective, NMDA, agonists, mGlur, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, Metabotropic, Non-selective, mGlu, 0285, Tocris Bioscience
4 Citations for Ibotenic acid
Citations are publications that use Tocris products. Selected citations for Ibotenic acid include:
Joseph et al (2018) Role of Prefrontal Cortex Anti- and Pro-inflammatory Cytokines in the Development of Abnormal Behaviors Induced by Disconnection of the Ventral Hippocampus in Neonate Rats. Front Behav Neurosci 12 244 PMID: 30459571
Karlsson et al (2013) Exaggerated cue-induced reinstatement of cocaine seeking but not incubation of cocaine craving in a developmental rat model of schizophrenia. Psychopharmacology (Berl) 226 45 PMID: 23010798
Pitts and Takahashi (2011) The central amygdala nucleus via corticotropin-releasing factor is necessary for time-limited consolidation processing but not storage of contextual fear memory. Neuroreport 95 86 PMID: 21093597
Renouard et al (2015) The supramammillary nucleus and the claustrum activate the cortex during REM sleep. Neurobiol Learn Mem 1 e1400177 PMID: 26601158
Do you know of a great paper that uses Ibotenic acid from Tocris? Please let us know.
Reviews for Ibotenic acid
There are currently no reviews for this product. Be the first to review Ibotenic acid and earn rewards!
Have you used Ibotenic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.